Drive Clinical and Economic Improvements With Cardiology’s New Paradigm

Read our report on heart care’s role in improving the business of healthcare 

 

AI-enabled CCTA care pathway helps avoid unnecessary spending

Health systems face both economic and regulatory pressure to reduce care costs and improve outcomes – and no specialty is immune to this pressure. Unlike current methods, Cleerly’s CCTA analysis powered by artificial intelligence (AI) enables providers to measure, track, and develop personalized heart health care plans based on the root causes of coronary artery disease (CAD). AI-enabled CCTA can help improve patient care, reduce unnecessary and expensive invasive procedures, support a transition to value-based care, and create positive, sustainable experiences for patients and providers.

37% increase
Healthcare labor expenses from pre‑pandemic levels 1

 

3.8% lower
2021 system operating margins vs. 2019 2

Cleerly's Business of Healthcare Report - Cover
 

Precision heart care’s role in supporting
The Business of Healthcare

Read the full report behind the economics of Cleerly’s AI-enabled CCTA analysis and its closed loop care pathway. We’ve detailed the economic stats and benefits, compared clinical utility against current methodology, and explained the significant impact on patient and provider experience.
 

Download Now
Learn More

Make a meaningful change in care quality and cost

Cleerly’s AI-enabled CCTA digital care pathway provides the personalized approach to cardiovascular care that healthcare has been seeking for decades. Whether you’re looking to improve patient care, avoid unnecessary and expensive invasive procedures, transition to value‑based care or improve physician retention – we’re here to help.

Contact us

References:
1 National Hospital Flash Report: January 2022. Kaufman Hall. Jan. 31, 2022.
2 A Special Workforce Edition of the National Hospital Flash Report. Kaufman Hall. May 11, 2022.

Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2024 Cleerly, Inc.